{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Auto-immunit\u00e9",
      "Autoimmunity",
      "Biological therapy",
      "Bioth\u00e9rapie",
      "Cancer",
      "Lymphoma",
      "Lymphomes",
      "Sj\u00f6gren's syndrome",
      "Syndrome de Gougerot-Sj\u00f6gren"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "24268698",
  "DateCompleted": {
    "Year": "2015",
    "Month": "01",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2016",
    "Month": "10",
    "Day": "18"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2013",
        "Month": "11",
        "Day": "21"
      }
    ],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "10.1016/j.revmed.2013.10.336",
      "S0248-8663(13)01063-1"
    ],
    "Journal": {
      "ISSN": "1768-3122",
      "JournalIssue": {
        "Volume": "35",
        "Issue": "5",
        "PubDate": {
          "Year": "2014",
          "Month": "May"
        }
      },
      "Title": "La Revue de medecine interne",
      "ISOAbbreviation": "Rev Med Interne"
    },
    "ArticleTitle": "[Autoimmune diseases and cancers. Part I: cancers complicating autoimmune diseases and their treatment].",
    "Pagination": {
      "StartPage": "310",
      "EndPage": "316",
      "MedlinePgn": "310-6"
    },
    "Abstract": {
      "AbstractText": [
        "The link between systemic disease and cancer is not fortuitous. An autoimmune disease can represent the starter for developing a non-Hodgkin lymphoma. This is particularly true for Sj\u00f6gren's syndrome that is associated with the highest risk of lymphoma (odds ratio up to 44). Other systemic autoimmune diseases concerned are systemic lupus with an odds ratio of 4.5 and rheumatoid arthritis with an odds ratio of 2 to 3. It is now well established that high inflammatory activity, rather than immunosuppressive treatment, is the major risk determinant. The association between solid cancer and autoimmune systemic disease is uncommon and concerns in particular scleroderma and lung cancer. Concerning biotherapy-induced cancers, there is no demonstrated increased risk with anti-TNF\u03b1 (except for cutaneous carcinoma and maybe melanoma) or with tocilizumab and abatacept even if studies with longer follow-up are needed at least for these two last drugs."
      ],
      "CopyrightInformation": "Copyright \u00a9 2013 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier SAS. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne-oncologie, h\u00f4pital d'instruction des arm\u00e9es Desgenettes, 108, boulevard Pinel, 69003 Lyon, France. Electronic address: florianpasquet@wanadoo.fr."
          }
        ],
        "LastName": "Pasquet",
        "ForeName": "F",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne-oncologie, h\u00f4pital d'instruction des arm\u00e9es Desgenettes, 108, boulevard Pinel, 69003 Lyon, France."
          }
        ],
        "LastName": "Pavic",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne, h\u00f4pital \u00c9douard-Herriot, 5, place d'Arsonval, 69003 Lyon cedex 03, France."
          }
        ],
        "LastName": "Ninet",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de m\u00e9decine interne, h\u00f4pital \u00c9douard-Herriot, 5, place d'Arsonval, 69003 Lyon cedex 03, France."
          }
        ],
        "LastName": "Hot",
        "ForeName": "A",
        "Initials": "A"
      }
    ],
    "PublicationTypeList": [
      "English Abstract",
      "Journal Article",
      "Review"
    ],
    "VernacularTitle": "Maladies auto-immunes et cancers. Premi\u00e8re partie\u00a0: cancers au cours des maladies auto-immunes et de leur traitement."
  },
  "MedlineJournalInfo": {
    "Country": "France",
    "MedlineTA": "Rev Med Interne",
    "NlmUniqueID": "8101383",
    "ISSNLinking": "0248-8663"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biological Products"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunosuppressive Agents"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "complications",
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Autoimmune Diseases"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Biological Products"
    },
    {
      "QualifierName": [
        "drug effects",
        "immunology"
      ],
      "DescriptorName": "Cell Transformation, Neoplastic"
    },
    {
      "QualifierName": [
        "immunology"
      ],
      "DescriptorName": "Drug-Related Side Effects and Adverse Reactions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Immunosuppressive Agents"
    },
    {
      "QualifierName": [
        "complications",
        "immunology"
      ],
      "DescriptorName": "Lymphoma"
    },
    {
      "QualifierName": [
        "chemically induced",
        "etiology",
        "immunology",
        "therapy"
      ],
      "DescriptorName": "Neoplasms"
    }
  ]
}